Video Messages and Vaccination Intention

December 6, 2021 updated by: Mireille Jacobson, University of Southern California

The Impact of Video Messaging on Vaccination Intention

This study uses an online panel survey to test the impact of video messages on stated likelihood of COVID-19 vaccination. Participants, who have self-identified as unvaccinated against COVID-19, are randomly assigned to either no video message or 1 of 3 video messages to encourage vaccine take-up. The key endpoint is a question about the likelihood of getting vaccinated in the next 30 days.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study uses an online panel survey to test the impact of video messages on stated likelihood of COVID-19 vaccination. Participants are recruited from the Prolific.co platform. Those who have indicated to Prolific that they have not been vaccinated will be randomly assigned to either no video message or 1 of 3 video messages created by the Vaccinate LA/USC collaborative. The key endpoint is a question about the likelihood of getting vaccinated in the next 30 days.

Study Type

Interventional

Enrollment (Actual)

1001

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90089
        • USC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adults in the Prolific.co panel
  • unvaccinated against COVID-19

Exclusion Criteria:

  • indicated to Prolific.co that they have received a COVID-19 vaccination

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
No video message
Experimental: Video message 1
Behavioral: Video messages
video messages aimed at increasing vaccination
Experimental: Video message 2
Behavioral: Video messages
video messages aimed at increasing vaccination
Experimental: Video message 3
Behavioral: Video messages
video messages aimed at increasing vaccination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vaccination intention
Time Frame: 30 days
Probability of getting vaccinated in the next 30 days
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 21, 2021

Primary Completion (Actual)

July 22, 2021

Study Completion (Actual)

July 22, 2021

Study Registration Dates

First Submitted

July 14, 2021

First Submitted That Met QC Criteria

July 22, 2021

First Posted (Actual)

July 28, 2021

Study Record Updates

Last Update Posted (Actual)

December 10, 2021

Last Update Submitted That Met QC Criteria

December 6, 2021

Last Verified

December 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • UP-21-00587

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Deidentified data will be shared after/concurrent with publication.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Analytic Code

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe